Stocks · Health care · Pharmaceutical Preparations

Janux Therapeutics, Inc.

JANX Clue Score43
United States Fiscal year ends December CIK 0001817713 Results filed 5 Nov 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Andrew Hollman Meyer
1 Dec 2025
Chief Business Officer
Sold after exercise
633
$33.52
$21.22K
Andrew Hollman Meyer
1 Dec 2025
Chief Business Officer
Sold after exercise
2,700
$32.85
$88.71K
Andrew Hollman Meyer
14 Nov 2025
Chief Business Officer
Sold after exercise
3,333
$30.00
$99.99K

What was left out

Form 4 filings counted 21
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 3
Sales at will 8
Transactions with no price 0
Shares from compensation/vesting 460,541
History held since 14 Jun 2021